COMPANY

Verity Pharmaceuticals

HQ: Toronto, Canada source · veritypharma.com ↗

Location: Toronto, Canada · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Bladder Cancer Bladder Cancer Recurrent Neoplasm Recurrence Urothelial Carcinoma Bladder Urothelial Carcinoma Recurrent Non-Invasive Bladder Urothelial Carcinoma

1Trials (company is sponsor)

Timeline

Apr 24, 2024 Trial start Phase 3: Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) source ↗

Upcoming milestones

2029-02 (ESTIMATED) · Phase 3 · Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) · NCT05037279

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT05037279	Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)	Phase 3	Recruiting	Apr 24, 2024	2029-02 (estimated)